Article

CM93, a novel covalent small molecule inhibitor targeting lung cancer with mutant EGFR

2020-03-11

Abstract excerpt

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have provided successful targeted therapies for patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Osimertinib (AZD9291) is a third-generation irreversible EGFR TKI that has received regulatory approval for overcoming resistance mediated by the EGFR T790M mutation as well as a first-line treatment targeting EGFR activating mutatio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f510766b-e74e-5a59-9860-dd8dc8ab1316
DOI: 10.1101/2020.03.09.984500

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CM93, a novel covalent small molecule inhibitor targeting lung cancer with mutant EGFRDOI 10.1101/2020.03.09.984500Read

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung CancerSemantic proximity Read

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.Semantic proximity Read

Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.Semantic proximity Read

Osimertinib making a breakthrough in lung cancer targeted therapySemantic proximity Read

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIsSemantic proximity Read

Targeting common EGFR mutations in non-small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors.Semantic proximity Read

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.Semantic proximity Read

Efficacy and safety of aumolertinib/icotinib combination therapy for naive EGFR-mutant non-small-cell lung cancer patients with brain metastases: A phase I/II study.Semantic proximity Read

JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.Semantic proximity Read

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.Semantic proximity Read

Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.Semantic proximity Read